MLYS Mineralys Therapeutics
- 12.250
- -0.120-0.97%
- 12.250
- 0.0000.00%
Mineralys Therapeutics News
Mineralys Therapeutics Board Member Announces Departure
Goldman Starts Mineralys at Buy, Cites Upcoming Drug Data
QuidelOrtho Stock Falls 11% on Savanna PVP4+ Assay Update
Express News | Mineralys Therapeutics Shares Are Trading Higher After Goldman Sachs Initiated Coverage on the Stock With a Buy Rating and Announced a Price Target of $30
Express News | Goldman Sachs Initiates Coverage On Mineralys Therapeutics With Buy Rating, Announces Price Target of $30
Mineralys Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/02/2024 126.93% Goldman Sachs → $30 Initiates Coverage On → Buy 08/08/2023 179.88% Credit Suisse $38 →
Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Q4 2023 Earnings Call Transcript
Analysts Offer Insights on Healthcare Companies: Resmed (RMD), Mineralys Therapeutics, Inc. (MLYS) and Addus Homecare (ADUS)
Buy Rating Affirmed for Mineralys Therapeutics Amid Positive Clinical and Strategic Developments
Earnings Call Summary | Mineralys Therapeutics(MLYS.US) Q4 2023 Earnings Conference
The following is a summary of the Mineralys Therapeutics, Inc. (MLYS) Q4 2023 Earnings Call Transcript:Financial Performance:Mineralys ended 2023 with cash, cash equivalents and investments totaling $
Mineralys Therapeutics Files Mixed-Securities Shelf Registration
Mineralys Therapeutics (MLYS) on Thursday filed a registration statement with the US Securities and Exchange Commission to sell up to $500 million of its securities from time to time. The securities m
Mineralys Therapeutics Inc (MLYS) Reports Increased R&D Expenses Amid Progress in ...
Mineralys Therapeutics Believes That Its Current Cash, Cash Equivalents and Investments Will Be Sufficient to Fund Its Planned Clinical Studies, as Well as Support Corporate Ops, Into 2026 >MLYS
Mineralys Therapeutics Believes That Its Current Cash, Cash Equivalents and Investments Will Be Sufficient to Fund Its Planned Clinical Studies, as Well as Support Corporate Ops, Into 2026 >MLYS
Mineralys Therapeutics Cash, Cash Equivalents and Investments Were $239M as of Dec 31 >MLYS
Mineralys Therapeutics Cash, Cash Equivalents and Investments Were $239M as of Dec 31 >MLYS
Express News | Mineralys Therapeutics Q4 EPS $(0.61) Beats $(0.82) Estimate
Mineralys Therapeutics 4Q Loss $24.4M >MLYS
Mineralys Therapeutics 4Q Loss $24.4M >MLYS
Press Release: Mineralys Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
Mineralys Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update -- Enrollment in the two pivotal trials of lorundrostat for the treatment of uHTN or r
Earnings Scheduled For March 21, 2024
Companies Reporting Before The Bell • Creative Realities (NASDAQ:CREX) is expected to report quarterly earnings at $0.02 per share on revenue of $16.47 million. • InflaRx (NASDAQ:IFRX) is projected to
If you're afraid the “Nolly” stock price will rise, consider this ETF that tracks “diet drug bulls”
Tema Pharmaceuticals and Investments (US stock code: HRTS), an ETF that tracks many pharmaceutical companies focused on the diet drug circuit, can be described as a very good choice. Industry ETF portfolios are diversified, and the volatility is often far less than individual stocks.
Mineralys Therapeutics Earnings Preview
Mineralys Therapeutics (NASDAQ:MLYS) is set to give its latest quarterly earnings report on Thursday, 2024-03-21. Here's what investors need to know before the announcement.Analysts estimate that Mine
Analysis
Price Target
No Data
